-
1.发明申请Conditionally replicative adenovirus to target the Rb and Rb-related pathways 审中-公开有条件复制的腺病毒靶向Rb和Rb相关途径公开(公告)号：US20050260162A1
公开(公告)日：2005-11-24
申请号：US11080248
申请日：2005-03-15
申请人： Juan Fueyo , Athanassios Kyritsis , Candelaria Gomez-Manzano , W. K. Yung , Polly Lee , Victor Levin , Charles Conrad , Frederick Lang
发明人： Juan Fueyo , Athanassios Kyritsis , Candelaria Gomez-Manzano , W. K. Yung , Polly Lee , Victor Levin , Charles Conrad , Frederick Lang
IPC分类号： A61K35/76 , A61K35/761 , A61K48/00 , C07K14/075 , C07K14/47 , C12N7/04 , C12N15/861 , C12Q1/68
CPC分类号： C12N7/00 , A61K35/761 , A61K45/06 , A61K48/00 , C07K14/005 , C07K14/4736 , C12N15/86 , C12N2710/10322 , C12N2710/10332 , C12N2710/10343 , C12N2710/10362 , A61K2300/00
摘要： The present invention involves a method of treating cancer using a mutant adenovirus that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming the cells with a wild type retinoblastoma pathway.
摘要翻译： 本发明涉及使用突变型视网膜母细胞瘤途径靶向细胞的突变型腺病毒来治疗癌症的方法。 突变型腺病毒能够杀死肿瘤细胞，而不会损害具有野生型视网膜母细胞瘤途径的细胞。
-
公开(公告)号：US20070292396A1
公开(公告)日：2007-12-20
申请号：US11681592
申请日：2007-03-02
CPC分类号： A61K35/761 , A61K45/06 , A61K2300/00
摘要： The present invention involves compositions and methods for treating cancer using a combination of cell cycle modulating agent(s) and anticancer agents or therapies, particularly S-phase specific therapies.
摘要翻译： 本发明涉及使用细胞周期调节剂和抗癌剂或治疗，特别是S期特异性疗法的组合来治疗癌症的组合物和方法。
-
公开(公告)号：US20060147420A1
公开(公告)日：2006-07-06
申请号：US11077513
申请日：2005-03-10
IPC分类号： A61K48/00
CPC分类号： A61K35/761 , A61K31/513 , A61K38/00 , A61K38/177 , A61K38/1891 , A61K38/50 , A61K45/06 , A61K48/005 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/10032 , C12N2710/10043 , C12N2710/10322 , C12N2710/10343 , C12N2710/10345 , C12Y305/04001 , A61K2300/00
摘要： The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
-
公开(公告)号：US20090175830A1
公开(公告)日：2009-07-09
申请号：US12370232
申请日：2009-02-12
申请人： Juan Fueyo , Candelaria Gomez-Manzano , W.K. Alfred Yung , Charles A. Conrad , Frederick F. Lang, JR.
发明人： Juan Fueyo , Candelaria Gomez-Manzano , W.K. Alfred Yung , Charles A. Conrad , Frederick F. Lang, JR.
CPC分类号： A61K35/761 , A61K31/513 , A61K38/00 , A61K38/177 , A61K38/1891 , A61K38/50 , A61K45/06 , A61K48/005 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/10032 , C12N2710/10043 , C12N2710/10322 , C12N2710/10343 , C12N2710/10345 , C12Y305/04001 , A61K2300/00
摘要： The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
摘要翻译： 本发明包括使用突变型腺病毒治疗癌症的组合物和方法，所述突变型腺病毒包含编码具有突变型视网膜母细胞瘤途径的细胞的治疗性多肽的多核苷酸。 突变型腺病毒能够杀死肿瘤细胞，而不会损害具有野生型视网膜母细胞瘤途径的细胞。
-
5.发明申请公开(公告)号：US20120207711A1
公开(公告)日：2012-08-16
申请号：US13444456
申请日：2012-04-11
CPC分类号： A61K48/0058 , A61K35/761 , A61K45/06 , A61K48/00 , A61K2300/00 , C07K16/081 , C07K2317/55 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10343 , C12N2710/10345 , C12N2810/40 , C12N2810/405 , C12N2810/6018 , C12N2810/851 , C12N2810/859 , C12N2830/008
摘要： A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.
摘要翻译： 提供能够克服肿瘤细胞上柯萨奇 - 腺病毒受体（CAR）表达低水平的问题的改良的腺病毒和使用这种腺病毒的方法。 通过插入或替换来修饰腺病毒的纤维蛋白，以将腺病毒靶向肿瘤细胞，由于E1a或E1b基因中的特异性启动子控制或突变，修饰的腺病毒的复制受限于肿瘤细胞。
-
公开(公告)号：US09061055B2
公开(公告)日：2015-06-23
申请号：US12370232
申请日：2009-02-12
申请人： Juan Fueyo , Candelaria Gomez-Manzano , W.K. Alfred Yung , Charles A. Conrad , Frederick F. Lang, Jr.
发明人： Juan Fueyo , Candelaria Gomez-Manzano , W.K. Alfred Yung , Charles A. Conrad , Frederick F. Lang, Jr.
IPC分类号： A61K48/00 , A61P35/00 , A61K38/17 , A61K38/50 , C07K14/005 , C12N7/00 , C12N15/86 , A61K38/18 , A61K45/06 , A61K35/761 , A61K38/00
CPC分类号： A61K35/761 , A61K31/513 , A61K38/00 , A61K38/177 , A61K38/1891 , A61K38/50 , A61K45/06 , A61K48/005 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/10032 , C12N2710/10043 , C12N2710/10322 , C12N2710/10343 , C12N2710/10345 , C12Y305/04001 , A61K2300/00
摘要： The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
摘要翻译： 本发明包括使用突变型腺病毒治疗癌症的组合物和方法，所述突变型腺病毒包含编码具有突变型视网膜母细胞瘤途径的细胞的治疗性多肽的多核苷酸。 突变型腺病毒能够杀死肿瘤细胞，而不会损害具有野生型视网膜母细胞瘤途径的细胞。
-
7.发明授权公开(公告)号：US08168168B2
公开(公告)日：2012-05-01
申请号：US12636134
申请日：2009-12-11
CPC分类号： A61K48/0058 , A61K35/761 , A61K45/06 , A61K48/00 , A61K2300/00 , C07K16/081 , C07K2317/55 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10343 , C12N2710/10345 , C12N2810/40 , C12N2810/405 , C12N2810/6018 , C12N2810/851 , C12N2810/859 , C12N2830/008
摘要： A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.
摘要翻译： 提供能够克服肿瘤细胞上柯萨奇 - 腺病毒受体（CAR）表达低水平的问题的改良的腺病毒和使用这种腺病毒的方法。 通过插入或替换来修饰腺病毒的纤维蛋白，以将腺病毒靶向肿瘤细胞，由于E1a或E1b基因中的特异性启动子控制或突变，修饰的腺病毒的复制受限于肿瘤细胞。
-
公开(公告)号：US20070212354A1
公开(公告)日：2007-09-13
申请号：US11373462
申请日：2006-03-10
IPC分类号： A61K39/395 , A61K38/18
CPC分类号： A61K38/179 , C07K2319/30
摘要： Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.
摘要翻译： 通过向人类患者施用有效量的血管内皮生长因子（VEGF）抑制剂来治疗患有脑肿瘤的人类患者，包括成胶质细胞瘤的方法。 VEGF抑制剂是包含具有两个具有SEQ ID NO：2的序列的融合多肽的二聚体蛋白质的VEGF拮抗剂蛋白质。
-
公开(公告)号：US07354582B2
公开(公告)日：2008-04-08
申请号：US11373462
申请日：2006-03-10
申请人： W. K. Alfred Yung , Candelaria Gomez-Manzano , Juan Fueyo , Jesse M. Cedarbaum , Jocelyn Holash
发明人： W. K. Alfred Yung , Candelaria Gomez-Manzano , Juan Fueyo , Jesse M. Cedarbaum , Jocelyn Holash
CPC分类号： A61K38/179 , C07K2319/30
摘要： Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.
摘要翻译： 通过向人类患者施用有效量的血管内皮生长因子（VEGF）抑制剂来治疗患有脑肿瘤的人类患者，包括成胶质细胞瘤的方法。 VEGF抑制剂是包含具有两个具有SEQ ID NO：2的序列的融合多肽的二聚体蛋白质的VEGF拮抗剂蛋白质。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.054 秒)
